Company Filing History:
Years Active: 2015
Title: The Innovations of Daniel Van Kammen
Introduction
Daniel Van Kammen is an accomplished inventor based in San Diego, CA. He has made significant contributions to the field of psychopharmacology through his innovative research and development of new treatment combinations for psychosis. His work focuses on enhancing the efficacy of antipsychotic medications while minimizing side effects.
Latest Patents
Daniel Van Kammen holds a patent for a groundbreaking combination of pimavanserin and risperidone for the treatment of psychosis. This patent demonstrates that the combination of 5-HT2A inverse agonists or antagonists, such as pimavanserin, with antipsychotics like risperidone can induce a rapid onset of antipsychotic action. Furthermore, this combination increases the number of responders compared to therapy with the antipsychotic alone. Notably, these effects can be achieved at a low dose of the antipsychotic, thereby reducing the incidence of side effects. The combinations are also effective at decreasing the incidence of weight gain and increased glucose or prolactin levels caused by the antipsychotic.
Career Highlights
Daniel Van Kammen has dedicated his career to advancing the treatment of psychosis. He is currently associated with Acadia Pharmaceuticals Inc., where he continues to innovate and develop new therapeutic strategies. His work has been instrumental in improving patient outcomes and enhancing the understanding of psychotropic medications.
Collaborations
Throughout his career, Daniel has collaborated with notable colleagues, including Perry Peters and David Furlano. These collaborations have fostered a productive environment for research and development, leading to significant advancements in the field.
Conclusion
Daniel Van Kammen's contributions to the field of psychopharmacology are noteworthy, particularly his innovative patent for the combination of pimavanserin and risperidone. His work exemplifies the potential for new treatment strategies to improve the lives of individuals suffering from psychosis.